{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:50:37Z","timestamp":1790679037500,"version":"4.1.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Organ transplantations are difficult, complicated and very expensive interventions. In order to preserve the transplanted organs, it is necessary to provide medical care to the patients in terms of immunosuppression. According to the guidelines, the first-line therapy choices for achieving immunosuppression after transplantation are tacrolimus, cyclosporine, mycophenolic acid, azathioprine, sirolimus, everolimus\u201e and corticosteroids. The aim of our study was to examine the utilization of this drugs in Montenegro and to compare the results with the ones from Finland, Croatia, and Serbia.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> In our investigation we used Anatomical Therapeutic Chemical\/Defined Daily Dose (ATC\/DDD) methodology. Prices per DDD of drugs are presented in euros (\u20ac).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> In all observed countries, there is a positive trend in the consumption of all 6 drugs during the analyzed period. The prices per DDD of these drugs generally show a negative trend. Tacrolimus and mycophenolic acid in Montenegro recorded the largest reduction in the price per DDD. Price per one DDD of tacrolimus decreased from \u20ac13.28 in 2009 to \u20ac5.11 in 2019, thus by about 260%, and as regards mycophenolic acid, the price per one DDD decreased from \u20ac9.59 in 2009 to \u20ac 3.36 in 2019, thus by almost 300%.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Despite the reduction in the price per DDD, drugs that are used as immunosuppressants are showing increasing costs from year to year. Since these drugs are expensive, they participate in a significant percentage in the budget for medicines in each country.<\/jats:p>","DOI":"10.3389\/fpubh.2021.671316","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T04:58:41Z","timestamp":1617166721000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Utilization of Mycophenolic Acid, Azathioprine, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus: Multinational Study"],"prefix":"10.3389","volume":"9","author":[{"given":"Majda","family":"Sahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snezana","family":"Mugosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nemanja","family":"Rancic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1440-1797.2007.00859.x","article-title":"Trends in adult post-kidney transplant immunosuppressive use in Australia, 1991-2005","volume":"13","author":"Chang","year":"2008","journal-title":"Nephrology"},{"key":"B2","first-page":"209","article-title":"Finansijski aspekti imunosupresivne terapije\/ financial aspects of immunosuppressive therapy","volume-title":"Immunosuppression Terapy and His Use in Transplantation of Organs","author":"Ridic","year":"2012"},{"key":"B3","first-page":"1","article-title":"2017 US organ and tissue transplant cost estimates and discussion","volume-title":"Millim Res Rep","author":"Bentley","year":"2017"},{"key":"B4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/j.1600-6143.2009.02834.x","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","author":"Kidney","year":"2009","journal-title":"Am J Transplant."},{"key":"B5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40472-015-0052-y","article-title":"The cost of transplant immunosuppressant therapy: is this sustainable?","volume":"2","author":"James","year":"2015","journal-title":"Curr Trans Rep."},{"key":"B6","first-page":"14","article-title":"Has the survival of the graft improved after renal transplantation in the era of modern immunosuppression?","volume":"33","author":"Moreso","year":"2013","journal-title":"Nefrologia"},{"key":"B7","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1056\/NEJM200003023420901","article-title":"Improved graft survival after renal transplantation in the United States, 1988 to 1996","volume":"342","author":"Hariharan","year":"2000","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/j.1600-6143.2004.00515.x","article-title":"Long-term renal allograft survival: have we made significant progress or it is time to rethink our analytic and therapeutic strategies?","volume":"4","author":"Meier-Kriesche","year":"2004","journal-title":"Am J Transplant."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/lt.20614","article-title":"Immuno-suppression in Liver Transplantation","volume":"11","author":"Post","year":"2005","journal-title":"Liver Transpl."},{"key":"B10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.5500\/wjt.v3.i4.68","article-title":"Novel immunosuppressive agents in kidney transplantation","volume":"3","author":"Hardinger","year":"2013","journal-title":"World J Transplant."},{"key":"B11","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s00108-013-3411-8","article-title":"Modern immunosuppression after solid organ transplantation","volume":"55","author":"Beimler","year":"2014","journal-title":"Der Internist."},{"key":"B12","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1097\/MNH.0000000000000065","article-title":"Role of pharmacogenomics in dialysis and transplantation","volume":"23","author":"Birdwell","year":"2014","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"B13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1615\/CritRevEukaryotGeneExpr.2015011421","article-title":"Current state of immunosuppression: past, present, and future","volume":"25","author":"Karam","year":"2015","journal-title":"Crit Rev Eukaryot Gene Expr."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1517\/14740338.2015.1040388","article-title":"Everolimus and sirolimus in transplantation-related but different","volume":"14","author":"Klawitter","year":"2015","journal-title":"Expert Opin Drug Saf."},{"key":"B15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.transproceed.2011.01.075","article-title":"Comparison of basiliximab and daclizumab with triple immunosuppression in renal transplantation","volume":"43","author":"Aktas","year":"2011","journal-title":"Transplant Proc."},{"key":"B16","unstructured":"Definition and General Consideration2013"},{"key":"B17","unstructured":"Consumption of Medicinal Products in Montenegro"},{"key":"B18","unstructured":"ALIMSPromet i Potro\u0161nja Lekova za Upotrebu u Humanoj Medicini"},{"key":"B19","volume-title":"Promet i Potro\u0161nja Gotovih Lekova za Humanu Upotrebu u Republici Srbiji u 2019 godini","author":"Radonji\u0107","year":"2020"},{"key":"B20","unstructured":"Promet"},{"key":"B21","unstructured":"Consumption- Fimea Englanti"},{"key":"B22","unstructured":"BredaA\n            BuddeK\n            FigueiredoA\n            Lled\u00f3Garc\u00eda E\n            OlsburghJ\n            RegeleH\n          UrowebRenal Transplantation | Uroweb2021"},{"key":"B23","volume-title":"\u017divot SA Presadenim Bubregom","author":"Hrva\u010devi\u0107","year":"2018"},{"key":"B24","unstructured":"LasicaD\n          Koliko Ko\u0161ta Zdravlje: Ima li Lijeka Za Skupe Lijekove"},{"key":"B25","unstructured":"2020"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.6002\/ect.2016.0157","article-title":"Two decades of tacrolimus in renal transplant: basic science and clinical evidences","volume":"15","author":"Shrestha","year":"2017","journal-title":"Exp Clin Transpl."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1111\/j.1600-6143.2011.03615.x","article-title":"The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function","volume":"11","author":"Momper","year":"2011","journal-title":"Am J Transplant."},{"key":"B28","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1136\/bmj.38569.471007.AE","article-title":"Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data","volume":"331","author":"Webster","year":"2005","journal-title":"BMJ."},{"key":"B29","unstructured":"Neoral Soft Gelatin Capsules - Summary of Product Characteristics (SmPC) - (emc)2020"},{"key":"B30","unstructured":"2020"},{"key":"B31","unstructured":"Institut za ljekove i medicinska sredstva Crne GoreIzvje\u0161taj o Utvrdenim Maksimalnim Cijenama Ljekova"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1111\/ajt.15809","article-title":"Tacrolimus- versus sirolimus-based immunosuppression after simultaneous pancreas and kidney transplantation: 5-year results of a randomized trial","volume":"20","author":"Cantarovich","year":"2020","journal-title":"Am J Transpl."},{"key":"B33","unstructured":"Everolimus 10mg Tablets - Summary of Product Characteristics (SmPC) - (emc)2020"},{"key":"B34","doi-asserted-by":"publisher","first-page":"150","DOI":"10.5500\/wjt.v8.i5.150","article-title":"Introduction of everolimus in kidney transplant recipients at a late posttransplant stage","volume":"8","author":"Uchida","year":"2018","journal-title":"World J Transpl."},{"key":"B35","unstructured":"A Lista_primena od 28.08.2020 [Internet]2020"},{"key":"B36","first-page":"14","article-title":"Conversion from tacrolimus to everolimus with complete and early glucocorticoid withdrawal after kidney transplantation: a randomised trial","volume":"76","author":"Bouamar","year":"2018","journal-title":"Neth J Med."},{"key":"B37","unstructured":"Azathioprine 50 mg Tablets - Summary of Product Characteristics (SmPC) - (emc) [Internet]2020"},{"key":"B38","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.healun.2018.03.012","article-title":"Azathioprine to mycophenolate mofetil transition and risk of squamous cell carcinoma after lung transplantation","volume":"37","author":"Vos","year":"2018","journal-title":"J Heart Lung Transpl."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2021.671316\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T04:58:51Z","timestamp":1617166731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2021.671316\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,31]]},"references-count":38,"alternative-id":["10.3389\/fpubh.2021.671316"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2021.671316","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,31]]},"article-number":"671316"}}